{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T17:33:02Z","timestamp":1790184782385,"version":"4.1.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,24]]},"DOI":"10.7759\/cureus.34158","type":"journal-article","created":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T19:06:16Z","timestamp":1674587176000},"source":"Crossref","is-referenced-by-count":6,"title":["An Overview of Fluvoxamine and its Use in SARS-CoV-2 Treatment"],"prefix":"10.7759","author":[{"given":"Naif   A","family":"Arishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naif  M","family":"Althomali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim M","family":"Dighriri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed S","family":"Alharthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghadeer B","family":"Alqurashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razan A","family":"Musharraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aeshah H","family":"Albuhayri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwah k","family":"Almalki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shatha A","family":"Alnami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zamzam O","family":"Mashraqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Fluvoxamine: clinical trials and clinical use","volume":"16","author":"Freeman CP","year":"1991","unstructured":"Freeman CP. Fluvoxamine: clinical trials and clinical use. J Psychiatry Neurosci. 1991, 16:19-25.","journal-title":"J Psychiatry Neurosci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199112003-00001","article-title":"A review of fluvoxamine and its uses in depression","volume":"6 Suppl 3","author":"Burton SW","year":"1991","unstructured":"Burton SW. A review of fluvoxamine and its uses in depression. Int Clin Psychopharmacol. 1991, 6 Suppl 3:1-17; discussion 17-21. 10.1097\/00004850-199112003-00001","journal-title":"Int Clin Psychopharmacol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.08.036","article-title":"Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival","volume":"131","author":"Hayashi T","year":"2007","unstructured":"Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Cell. 2007, 131:596-610. 10.1016\/j.cell.2007.08.036","journal-title":"Cell"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(96)00254-3","article-title":"Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain","volume":"307","author":"Narita N","year":"1996","unstructured":"Narita N, Hashimoto K, Tomitaka S, Minabe Y. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol. 1996, 307:117-9. 10.1016\/0014-2999(96)00254-3","journal-title":"Eur J Pharmacol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau5266","article-title":"Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis","volume":"11","author":"Rosen DA","year":"2019","unstructured":"Rosen DA, Seki SM, Fern\u00e1ndez-Casta\u00f1eda A, Beiter RM, Eccles JD, Woodfolk JA, Gaultier A. Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis. Sci Transl Med. 2019, 11:10.1126\/scitranslmed.aau5266","journal-title":"Sci Transl Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.652688","article-title":"Fluvoxamine: a review of its mechanism of action and its role in COVID-19","volume":"12","author":"Sukhatme VP","year":"2021","unstructured":"Sukhatme VP, Reiersen AM, Vayttaden SJ, Sukhatme VV. Fluvoxamine: a review of its mechanism of action and its role in COVID-19. Front Pharmacol. 2021, 12:652688. 10.3389\/fphar.2021.652688","journal-title":"Front Pharmacol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X19666210729123734","article-title":"Fluvoxamine and amantadine: central nervous system acting drugs repositioned for COVID-19 as early intervention","volume":"20","author":"Rejdak K","year":"2022","unstructured":"Rejdak K, Grieb P. Fluvoxamine and amantadine: central nervous system acting drugs repositioned for COVID-19 as early intervention. Curr Neuropharmacol. 2022, 20:777-81. 10.2174\/1570159X19666210729123734","journal-title":"Curr Neuropharmacol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002558","article-title":"Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP3 receptors and cellular signaling pathways","volume":"3","author":"Nishimura T","year":"2008","unstructured":"Nishimura T, Ishima T, Iyo M, Hashimoto K. Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP3 receptors and cellular signaling pathways. PLoS One. 2008, 3:e2558. 10.1371\/journal.pone.0002558","journal-title":"PLoS One"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-04968-z","article-title":"Fluvoxamine stimulates oligodendrogenesis of cultured neural stem cells and attenuates inflammation and demyelination in an animal model of multiple sclerosis","volume":"7","author":"Ghareghani M","year":"2017","unstructured":"Ghareghani M, Zibara K, Sadeghi H, Dokoohaki S, Sadeghi H, Aryanpour R, Ghanbari A. Fluvoxamine stimulates oligodendrogenesis of cultured neural stem cells and attenuates inflammation and demyelination in an animal model of multiple sclerosis. Sci Rep. 2017, 7:4923. 10.1038\/s41598-017-04968-z","journal-title":"Sci Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0106533","article-title":"Psychedelic N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine modulate innate and adaptive inflammatory responses through the sigma-1 receptor of human monocyte-derived dendritic cells","volume":"9","author":"Szabo A","year":"2014","unstructured":"Szabo A, Kovacs A, Frecska E, Rajnavolgyi E. Psychedelic N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine modulate innate and adaptive inflammatory responses through the sigma-1 receptor of human monocyte-derived dendritic cells. PLoS One. 2014, 9:e106533. 10.1371\/journal.pone.0106533","journal-title":"PLoS One"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2007.03.010","article-title":"Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression","volume":"17","author":"Taler M","year":"2007","unstructured":"Taler M, Gil-Ad I, Lomnitski L, et al.. Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression. Eur Neuropsychopharmacol. 2007, 17:774-80. 10.1016\/j.euroneuro.2007.03.010","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen N","year":"2020","unstructured":"Chen N, Zhou M, Dong X, et al.. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020, 395:507-13. 10.1016\/S0140-6736(20)30211-7","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00983-12","article-title":"Fluoxetine is a potent inhibitor of coxsackievirus replication","volume":"56","author":"Zuo J","year":"2012","unstructured":"Zuo J, Quinn KK, Kye S, Cooper P, Damoiseaux R, Krogstad P. Fluoxetine is a potent inhibitor of coxsackievirus replication. Antimicrob Agents Chemother. 2012, 56:4838-44. 10.1128\/AAC.00983-12","journal-title":"Antimicrob Agents Chemother"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.582310","article-title":"Repurposing sigma-1 receptor ligands for COVID-19 therapy?","volume":"11","author":"Vela JM","year":"2020","unstructured":"Vela JM. Repurposing sigma-1 receptor ligands for COVID-19 therapy?. Front Pharmacol. 2020, 11:582310. 10.3389\/fphar.2020.582310","journal-title":"Front Pharmacol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15126","article-title":"Safety and efficacy of fluvoxamine in COVID-19 ICU patients: An open label, prospective cohort trial with matched controls","volume":"88","author":"Calusic M","year":"2022","unstructured":"Calusic M, Marcec R, Luksa L, Jurkovic I, Kovac N, Mihaljevic S, Likic R. Safety and efficacy of fluvoxamine in COVID-19 ICU patients: An open label, prospective cohort trial with matched controls. Br J Clin Pharmacol. 2022, 88:2065-73. 10.1111\/bcp.15126","journal-title":"Br J Clin Pharmacol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031716","article-title":"SARS-CoV-2-specific immune response and the pathogenesis of COVID-19","volume":"23","author":"Gusev E","year":"2022","unstructured":"Gusev E, Sarapultsev A, Solomatina L, Chereshnev V. SARS-CoV-2-specific immune response and the pathogenesis of COVID-19. Int J Mol Sci. 2022, 23:1716. 10.3390\/ijms23031716","journal-title":"Int J Mol Sci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2020.05.002","article-title":"COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons","volume":"53","author":"Nile SH","year":"2020","unstructured":"Nile SH, Nile A, Qiu J, Li L, Jia X, Kai G. COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons. Cytokine Growth Factor Rev. 2020, 53:66-70. 10.1016\/j.cytogfr.2020.05.002","journal-title":"Cytokine Growth Factor Rev"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann M","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, et al.. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020, 181:271-280.e8. 10.1016\/j.cell.2020.02.052","journal-title":"Cell"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26234","article-title":"Emerging coronaviruses: Genome structure, replication, and pathogenesis","volume":"92","author":"Chen Y","year":"2020","unstructured":"Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol. 2020, 92:2249. 10.1002\/jmv.26234","journal-title":"J Med Virol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-021-00630-8","article-title":"Structural biology of SARS-CoV-2 and implications for therapeutic development","volume":"19","author":"Yang H","year":"2021","unstructured":"Yang H, Rao Z. Structural biology of SARS-CoV-2 and implications for therapeutic development. Nat Rev Microbiol. 2021, 19:685-700. 10.1038\/s41579-021-00630-8","journal-title":"Nat Rev Microbiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2021.02.036","article-title":"The SARS-CoV-2 subgenome landscape and its novel regulatory features","volume":"81","author":"Wang D","year":"2021","unstructured":"Wang D, Jiang A, Feng J, et al.. The SARS-CoV-2 subgenome landscape and its novel regulatory features. Mol Cell. 2021, 81:2135-2147.e5. 10.1016\/j.molcel.2021.02.036","journal-title":"Mol Cell"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2006.11.027","article-title":"The intracellular sites of early replication and budding of SARS-coronavirus","volume":"361","author":"Stertz S","year":"2007","unstructured":"Stertz S, Reichelt M, Spiegel M, et al.. The intracellular sites of early replication and budding of SARS-coronavirus. Virology. 2007, 361:304-15. 10.1016\/j.virol.2006.11.027","journal-title":"Virology"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106044","article-title":"Widely available lysosome targeting agents should be considered as potential therapy for COVID-19","volume":"56","author":"Homolak J","year":"2020","unstructured":"Homolak J, Kodvanj I. Widely available lysosome targeting agents should be considered as potential therapy for COVID-19. Int J Antimicrob Agents. 2020, 56:106044. 10.1016\/j.ijantimicag.2020.106044","journal-title":"Int J Antimicrob Agents"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01658-17","article-title":"Expression and cleavage of Middle East Respiratory Syndrome coronavirus nsp3-4 polyprotein induce the formation of double-membrane vesicles that mimic those associated with coronaviral RNA replication","volume":"8","author":"Oudshoorn D","year":"2017","unstructured":"Oudshoorn D, Rijs K, Limpens RW, et al.. Expression and cleavage of Middle East Respiratory Syndrome coronavirus nsp3-4 polyprotein induce the formation of double-membrane vesicles that mimic those associated with coronaviral RNA replication. mBio. 2017, 8:e01658-17. 10.1128\/mBio.01658-17","journal-title":"mBio"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2015.03.013","article-title":"Cellular stress responses in hepatitis C virus infection: Mastering a two-edged sword","volume":"209","author":"Vasallo C","year":"2015","unstructured":"Vasallo C, Gastaminza P. Cellular stress responses in hepatitis C virus infection: Mastering a two-edged sword. Virus Res. 2015, 209:100-17. 10.1016\/j.virusres.2015.03.013","journal-title":"Virus Res"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03557-12","article-title":"Sigma-1 receptor regulates early steps of viral RNA replication at the onset of hepatitis C virus infection","volume":"87","author":"Friesland M","year":"2013","unstructured":"Friesland M, Mingorance L, Chung J, Chisari FV, Gastaminza P. Sigma-1 receptor regulates early steps of viral RNA replication at the onset of hepatitis C virus infection. J Virol. 2013, 87:6377-90. 10.1128\/JVI.03557-12","journal-title":"J Virol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2286-9","article-title":"A SARS-CoV-2 protein interaction map reveals targets for drug repurposing","volume":"583","author":"Gordon DE","year":"2020","unstructured":"Gordon DE, Jang GM, Bouhaddou M, et al.. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020, 583:459-68. 10.1038\/s41586-020-2286-9","journal-title":"Nature"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02619-14","article-title":"Selective inhibition of hepatitis C virus infection by hydroxyzine and benztropine","volume":"58","author":"Mingorance L","year":"2014","unstructured":"Mingorance L, Friesland M, Coto-Llerena M, et al.. Selective inhibition of hepatitis C virus infection by hydroxyzine and benztropine. Antimicrob Agents Chemother. 2014, 58:3451-60. 10.1128\/AAC.02619-14","journal-title":"Antimicrob Agents Chemother"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3390\/v8070184","article-title":"Regulation of stress responses and translational control by coronavirus","volume":"8","author":"Fung TS","year":"2016","unstructured":"Fung TS, Liao Y, Liu DX. Regulation of stress responses and translational control by coronavirus. Viruses. 2016, 8:184. 10.3390\/v8070184","journal-title":"Viruses"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00659-06","article-title":"Modulation of the unfolded protein response by the severe acute respiratory syndrome coronavirus spike protein","volume":"80","author":"Chan CP","year":"2006","unstructured":"Chan CP, Siu KL, Chin KT, Yuen KY, Zheng B, Jin DY. Modulation of the unfolded protein response by the severe acute respiratory syndrome coronavirus spike protein. J Virol. 2006, 80:9279-87. 10.1128\/JVI.00659-06","journal-title":"J Virol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/febs.16163","article-title":"Protons to Patients: targeting endosomal Na(+) \/H(+) exchangers against COVID-19 and other viral diseases","volume":"288","author":"Prasad H","year":"2021","unstructured":"Prasad H. Protons to Patients: targeting endosomal Na(+) \/H(+) exchangers against COVID-19 and other viral diseases. FEBS J. 2021, 288:5071-88. 10.1111\/febs.16163","journal-title":"FEBS J"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-7091-1368-4","article-title":"Acid aphingomyelinase","author":"Henry B","year":"2013","unstructured":"Henry B, Ziobro R, Becker KA, Kolesnick R, Gulbins E. Acid aphingomyelinase.  Sphingolipids: Basic Science and Drug Development. Gulbins E, Petrache I (ed): Springer, Vienna; 2013. 77-88. 10.1007\/978-3-7091-1368-4"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115676","article-title":"Ceramide and related molecules in viral infections","volume":"22","author":"Beckmann N","year":"2021","unstructured":"Beckmann N, Becker KA. Ceramide and related molecules in viral infections. Int J Mol Sci. 2021, 22:5676. 10.3390\/ijms22115676","journal-title":"Int J Mol Sci"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01964-12","article-title":"Gangliosides have a functional role during rotavirus cell entry","volume":"87","author":"Mart\u00ednez MA","year":"2013","unstructured":"Mart\u00ednez MA, L\u00f3pez S, Arias CF, Isa P. Gangliosides have a functional role during rotavirus cell entry. J Virol. 2013, 87:1115-22. 10.1128\/JVI.01964-12","journal-title":"J Virol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2008.02.023","article-title":"Lipid rafts are involved in SARS-CoV entry into Vero E6 cells","volume":"369","author":"Lu Y","year":"2008","unstructured":"Lu Y, Liu DX, Tam JP. Lipid rafts are involved in SARS-CoV entry into Vero E6 cells. Biochem Biophys Res Commun. 2008, 369:344-9. 10.1016\/j.bbrc.2008.02.023","journal-title":"Biochem Biophys Res Commun"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100142","article-title":"Pharmacological inhibition of acid sphingomyelinase prevents uptake of SARS-CoV-2 by epithelial cells","volume":"1","author":"Carpinteiro A","year":"2020","unstructured":"Carpinteiro A, Edwards MJ, Hoffmann M, et al.. Pharmacological inhibition of acid sphingomyelinase prevents uptake of SARS-CoV-2 by epithelial cells. Cell Rep Med. 2020, 1:100142. 10.1016\/j.xcrm.2020.100142","journal-title":"Cell Rep Med"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1515\/hsz-2019-0270","article-title":"Emerging mechanisms of drug-induced phospholipidosis","volume":"401","author":"Breiden B","year":"2019","unstructured":"Breiden B, Sandhoff K. Emerging mechanisms of drug-induced phospholipidosis. Biol Chem. 2019, 401:31-46. 10.1515\/hsz-2019-0270","journal-title":"Biol Chem"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1829082","article-title":"Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine","volume":"9","author":"Schloer S","year":"2020","unstructured":"Schloer S, Brunotte L, Goretzko J, et al.. Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine. Emerg Microbes Infect. 2020, 9:2245-55. 10.1080\/22221751.2020.1829082","journal-title":"Emerg Microbes Infect"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1177\/1535370216643769","article-title":"Repeatedly administered antidepressant drugs modulate humoral and cellular immune response in mice through action on macrophages","volume":"241","author":"Nazimek K","year":"2016","unstructured":"Nazimek K, Kozlowski M, Bryniarski P, et al.. Repeatedly administered antidepressant drugs modulate humoral and cellular immune response in mice through action on macrophages. Exp Biol Med (Maywood). 2016, 241:1540-50. 10.1177\/1535370216643769","journal-title":"Exp Biol Med (Maywood)"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.5114\/fn.2021.107572","article-title":"Are central nervous system drugs displaying anti-inflammatory activity suitable for early treatment of COVID-19?","volume":"59","author":"Grieb P","year":"2021","unstructured":"Grieb P, Rejdak K. Are central nervous system drugs displaying anti-inflammatory activity suitable for early treatment of COVID-19?. Folia Neuropathol. 2021, 59:113-20. 10.5114\/fn.2021.107572","journal-title":"Folia Neuropathol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2010.06.014","article-title":"Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression","volume":"35","author":"Maes M","year":"2011","unstructured":"Maes M. Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2011, 35:664-75. 10.1016\/j.pnpbp.2010.06.014","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2016.07.001","article-title":"The role of macrophages in anti-inflammatory activity of antidepressant drugs","volume":"222","author":"Nazimek K","year":"2017","unstructured":"Nazimek K, Strobel S, Bryniarski P, Kozlowski M, Filipczak-Bryniarska I, Bryniarski K. The role of macrophages in anti-inflammatory activity of antidepressant drugs. Immunobiology. 2017, 222:823-30. 10.1016\/j.imbio.2016.07.001","journal-title":"Immunobiology"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2014.01.064","article-title":"Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells","volume":"727","author":"Ishima T","year":"2014","unstructured":"Ishima T, Fujita Y, Hashimoto K. Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells. Eur J Pharmacol. 2014, 727:167-73. 10.1016\/j.ejphar.2014.01.064","journal-title":"Eur J Pharmacol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232113623","article-title":"Antiviral and anti-inflammatory activities of fluoxetine in a SARS-CoV-2 infection mouse model","volume":"23","author":"P\u00e9ricat D","year":"2022","unstructured":"P\u00e9ricat D, Leon-Icaza SA, Sanchez Rico M, et al.. Antiviral and anti-inflammatory activities of fluoxetine in a SARS-CoV-2 infection mouse model. Int J Mol Sci. 2022, 23:13623. 10.3390\/ijms232113623","journal-title":"Int J Mol Sci"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007214","article-title":"Platelet gene expression and function in patients with COVID-19","volume":"136","author":"Manne BK","year":"2020","unstructured":"Manne BK, Denorme F, Middleton EA, et al.. Platelet gene expression and function in patients with COVID-19. Blood. 2020, 136:1317-29. 10.1182\/blood.2020007214","journal-title":"Blood"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007252","article-title":"Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19","volume":"136","author":"Hottz ED","year":"2020","unstructured":"Hottz ED, Azevedo-Quintanilha IG, Palhinha L, et al.. Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19. Blood. 2020, 136:1330-41. 10.1182\/blood.2020007252","journal-title":"Blood"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-437392","article-title":"Platelet serotonin promotes the recruitment of neutrophils to sites of acute inflammation in mice","volume":"121","author":"Duerschmied D","year":"2013","unstructured":"Duerschmied D, Suidan GL, Demers M, et al.. Platelet serotonin promotes the recruitment of neutrophils to sites of acute inflammation in mice. Blood. 2013, 121:1008-15. 10.1182\/blood-2012-06-437392","journal-title":"Blood"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.6.1165","article-title":"Relationship between release of platelet\/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression","volume":"162","author":"Serebruany VL","year":"2005","unstructured":"Serebruany VL, Suckow RF, Cooper TB, et al.. Relationship between release of platelet\/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. Am J Psychiatry. 2005, 162:1165-70. 10.1176\/appi.ajp.162.6.1165","journal-title":"Am J Psychiatry"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.12659\/msm.881924","article-title":"Serotonin reuptake inhibitor antidepressants (SSRIs) against atherosclerosis","volume":"17","author":"Wozniak G","year":"2011","unstructured":"Wozniak G, Toska A, Saridi M, Mouzas O. Serotonin reuptake inhibitor antidepressants (SSRIs) against atherosclerosis. Med Sci Monit. 2011, 17:RA205-14. 10.12659\/msm.881924","journal-title":"Med Sci Monit"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.22760","article-title":"Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial","volume":"324","author":"Lenze EJ","year":"2020","unstructured":"Lenze EJ, Mattar C, Zorumski CF, et al.. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA. 2020, 324:2292-300. 10.1001\/jama.2020.22760","journal-title":"JAMA"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab050","article-title":"Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19","volume":"8","author":"Seftel D","year":"2021","unstructured":"Seftel D, Boulware DR. Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19. Open Forum Infect Dis. 2021, 8:ofab050. 10.1093\/ofid\/ofab050","journal-title":"Open Forum Infect Dis"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(21)00448-4","article-title":"Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID- 19: the TOGETHER randomised, platform clinical trial","volume":"10","author":"Reis G","year":"2022","unstructured":"Reis G, Dos Santos Moreira-Silva EA, Silva DC, et al..  Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID- 19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2022, 10:e42-51. 10.1016\/S2214-109X(21)00448-4","journal-title":"Lancet Glob Health"},{"key":"ref53","unstructured":"Fluvoxamine for Early Treatment of Covid-19 (Stop Covid 2). (2020). Accessed. December 8, 2022: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT04668950.?view=results."},{"key":"ref54","unstructured":"COVID-OUT. Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19). (2020). Accessed: December 8, 2022: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04510194."},{"key":"ref55","unstructured":"ACTIV-6. COVID-19 Study of Repurposed Medications. (2021). Accessed: December 9, 2022: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04885530."},{"key":"ref56","unstructured":"Fluvoxamine Administration in Moderate SARS-CoV-2 (COVID-19) Infected Patients. (2021). Accessed. December 9, 2022: https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT04718480."},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199400940-00001","article-title":"Fluvoxamine. A review of its safety profile in world-wide studies","volume":"9","author":"Wagner W","year":"1994","unstructured":"Wagner W, Zaborny BA, Gray TE. Fluvoxamine. A review of its safety profile in world-wide studies. Int Clin Psychopharmacol. 1994, 9:223-7. 10.1097\/00004850-199400940-00001","journal-title":"Int Clin Psychopharmacol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2015.1021331","article-title":"Pharmacokinetic evaluation of fluvoxamine for the treatment of anxiety disorders","volume":"11","author":"Altamura AC","year":"2015","unstructured":"Altamura AC, Caldiroli A, Buoli M. Pharmacokinetic evaluation of fluvoxamine for the treatment of anxiety disorders. Expert Opin Drug Metab Toxicol. 2015, 11:649-60. 10.1517\/17425255.2015.1021331","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1111\/j.1368-5031.2006.00865.x","article-title":"Tolerability and safety of fluvoxamine and other antidepressants","volume":"60","author":"Westenberg HG","year":"2006","unstructured":"Westenberg HG, Sandner C. Tolerability and safety of fluvoxamine and other antidepressants. Int J Clin Pract. 2006, 60:482-91. 10.1111\/j.1368-5031.2006.00865.x","journal-title":"Int J Clin Pract"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199200432-00008","article-title":"Review of fluvoxamine safety database","volume":"43 Suppl 2","author":"Wagner W","year":"1992","unstructured":"Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H. Review of fluvoxamine safety database. Drugs. 1992, 43 Suppl 2:48-53; discussion 53-4. 10.2165\/00003495-199200432-00008","journal-title":"Drugs"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.2174\/1389200023338017","article-title":"Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update","volume":"3","author":"Hemeryck A","year":"2002","unstructured":"Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab. 2002, 3:13-37. 10.2174\/1389200023338017","journal-title":"Curr Drug Metab"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199500291-00006","article-title":"Fluvoxamine. A review of global drug-drug interaction data","volume":"29 Suppl 1","author":"Wagner W","year":"1995","unstructured":"Wagner W, Vause EW. Fluvoxamine. A review of global drug-drug interaction data. Clin Pharmacokinet. 1995, 29 Suppl 1:26-31; discussion 31-2. 10.2165\/00003088-199500291-00006","journal-title":"Clin Pharmacokinet"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2000.10.295","article-title":"The effect of fluvoxamine and behavior therapy on children and adolescents with obsessive-compulsive disorder","volume":"10","author":"Neziroglu F","year":"2000","unstructured":"Neziroglu F, Yaryura-Tobias JA, Walz J, McKay D. The effect of fluvoxamine and behavior therapy on children and adolescents with obsessive-compulsive disorder. J Child Adolesc Psychopharmacol. 2000, 10:295-306. 10.1089\/cap.2000.10.295","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2006.16.159","article-title":"Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: children versus adolescents","volume":"16","author":"Safer DJ","year":"2006","unstructured":"Safer DJ, Zito JM. Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: children versus adolescents. J Child Adolesc Psychopharmacol. 2006, 16:159-69. 10.1089\/cap.2006.16.159","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1177\/070674370905400405","article-title":"Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study","volume":"54","author":"Einarson A","year":"2009","unstructured":"Einarson A, Choi J, Einarson TR, Koren G. Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study. Can J Psychiatry. 2009, 54:242-6. 10.1177\/070674370905400405","journal-title":"Can J Psychiatry"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h1798","article-title":"Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design","volume":"350","author":"Furu K","year":"2015","unstructured":"Furu K, Kieler H, Haglund B, et al.. Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design. BMJ. 2015, 350:h1798. 10.1136\/bmj.h1798","journal-title":"BMJ"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.5605","article-title":"Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn","volume":"313","author":"Huybrechts KF","year":"2015","unstructured":"Huybrechts KF, Bateman BT, Palmsten K, et al.. Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn. JAMA. 2015, 313:2142-51. 10.1001\/jama.2015.5605","journal-title":"JAMA"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/132205-an-overview-of-fluvoxamine-and-its-use-in-sars-cov-2-treatment","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:57:19Z","timestamp":1707508639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/132205-an-overview-of-fluvoxamine-and-its-use-in-sars-cov-2-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,24]]},"references-count":67,"URL":"https:\/\/doi.org\/10.7759\/cureus.34158","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,24]]}}}